Table 1.
Characteristics of patients according to the expression of indoleamine 2,3-dioxygenase (IDO1) in tubules. Data are presented as the mean ± standard deviation.
| Patient Characteristics | IDO1 Expression in Tubules IDO1(+) Positive n = 76 | IDO1 Expression in Tubules IDO1(−) Negative n = 45 | p |
|---|---|---|---|
| Recipient’s age (years) | 39.8 ± 14 | 45.6 ± 14 | 0.03 |
| Male gender (n, %) | 54 (71%) | 31 (68.8%) | 0.8 |
| Number of HLA * ABDR ** mismatches |
3.52 ± 0.9 | 3.57 ± 1.3 | 0.84 |
| A | 1.32 ± 0.5 | 1.27 ± 0.5 | 0.71 |
| B | 1.48 ± 0.5 | 1.27 ± 0.6 | 0.08 |
| DR | 0.71 ± 0.5 | 1.027 ± 0.5 | 0.007 |
| Percentage of pre-sensitized patients |
|||
| PRA *** < 10% | 37/49 (75.5%) | 19/29 (65.5%) | 0.34 |
| PRA 10–50% | 10/49 (23.1%) | 7/29 (13.5%) | 0.69 |
| PRA > 50% | 2/49 (4%) | 3/29 (10%) | 0.25 |
| Cold ischemia time (hours) | 22.2 ± 8.1 | 21.9 ± 8.6 | 0.87 |
| Donor male gender (n, %) | 36/59 (61%) | 17/30 (56%) | 0.69 |
| Donor age (years) | 46.8 ± 13.7 | 50.5 ± 17.3 | 0.34 |
* Human Leukocyte Antigen. ** HLA-A, HLA-B (Class I) and HLA-DR (Class II)—specific classes of HLA genes. *** Panel Reactive Antibody.